Pentosan Polysulfate
A compound derived from beechwood. FDA-approved orally (Elmiron) for bladder pain (interstitial cystitis), commonly used as an injection for joint and cartilage repair in osteoarthritis. One of the most popular peptide-adjacent therapies in sports medicine and regenerative clinics. Mimics natural compounds in cartilage to protect joints and reduce inflammation.
Dosage
| Weight | Suggested Dose |
|---|---|
| 60 kg / 130 lbs | 120-180 mg subcutaneous 1-2x weekly |
| 75 kg / 165 lbs | 150-225 mg subcutaneous 1-2x weekly |
| 90 kg / 200 lbs | 180-270 mg subcutaneous 1-2x weekly |
| 115 kg / 250 lbs | 230-345 mg subcutaneous 1-2x weekly |
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Oral capsule or subcutaneous/intramuscular injection
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Cartilage Repair
Stimulates proteoglycan synthesis and inhibits matrix metalloproteinases.
Joint Lubrication
Enhances hyaluronic acid synthesis for improved synovial fluid properties.
Anti-Inflammatory
Inhibits complement activation and reduces fibrin deposits in joints.
Mechanism of Action
Pentosan Polysulfate (PPS) is a semi-synthetic, sulfated polysaccharide derived from beechwood hemicellulose (xylan). Its structure consists of a xylose backbone with sulfate ester groups at positions 2 and 3, giving it a high negative charge density similar to heparin and endogenous glycosaminoglycans like heparan sulfate. This polyanionic character is central to its multiple mechanisms of action.
In joint and cartilage repair, PPS stimulates chondrocyte proteoglycan synthesis — the production of aggrecan and other proteoglycans that form the hydrated gel matrix of articular cartilage. Proteoglycans are responsible for cartilage's compressive resilience and water retention, and their loss is a hallmark of osteoarthritis. PPS also inhibits matrix metalloproteinases (MMPs), particularly MMP-3, MMP-9, and MMP-13, which are the enzymes responsible for cartilage matrix degradation in osteoarthritis. By simultaneously promoting matrix synthesis and inhibiting matrix breakdown, PPS shifts the balance toward cartilage repair. Additionally, PPS improves synovial fluid viscosity by stimulating hyaluronic acid synthesis from synoviocytes, partially restoring the lubrication and shock-absorbing properties lost in arthritic joints.
PPS has several additional pharmacological properties. It inhibits complement activation (particularly the alternative pathway), reducing inflammatory damage to joint tissues. It has fibrinolytic activity — promoting the dissolution of fibrin deposits that can form in inflamed synovial tissue and contribute to joint adhesions. It inhibits certain lipases and has lipid-clearing properties. In its FDA-approved indication (interstitial cystitis), PPS is thought to replenish the damaged glycosaminoglycan layer lining the bladder epithelium, restoring the protective barrier against urine irritants. The recent FDA warning about retinal pigmentary maculopathy with long-term oral use (affecting approximately 1 in 4 long-term users) appears to be related to accumulation of PPS metabolites in the retinal pigment epithelium, where they may disrupt lysosomal function and pigment recycling.
Regulatory Status
FDA approved as Elmiron (oral) for interstitial cystitis. Injectable form used widely in veterinary medicine and available through compounding pharmacies for human use.
Risks & Safety
Common
bruising, injection site pain, headache, nausea, diarrhea, hair loss (oral).
Serious
retinal pigmentary maculopathy with long-term oral use (FDA warning — unique, potentially irreversible vision damage), liver damage (rare).
Rare
low platelet count, severe allergic reactions. Regular eye exams recommended with oral use beyond 2 years.
Compare Pentosan Polysulfate With
Research Papers
11Published: September 16, 2026
AI Summary
We evaluated the value of baseline structural optical coherence tomography (OCT) biomarkers in determining functional treatment response at 6,12-, and 24-months following treatment initiation in patients undergoing anti-vascular endothelial growth factor, steroid, or laser treatment for diabetic macular edema (DME). Ovid MEDLINE, EMBASE, and Web of Science databases were searched from inception...
Published: September 3, 2026
AI Summary
This systematic review examines the prognostic value of baseline optical coherence tomography (OCT) biomarkers in predicting visual acuity (VA) outcomes for eyes with macular edema secondary to retinal vein occlusions (RVO) treated with anti-VEGF therapies, steroids, laser photocoagulation, or combination treatments. VA predictions at 6, 12, and 24 months post-treatment were assessed using a na...
Published: October 3, 2024
AI Summary
Moderate to severe interstitial cystitis (also known as bladder pain syndrome) is a disabling disease with no effective treatment. Although pentosan polysulfate is an approved treatment for interstitial cystitis, some patients on this medication experience treatment failure after one year, and its long-term use has been linked to pigmentary maculopathy. The peptide Body Protective Compound 157 ...
Published: September 30, 2023
AI Summary
Genetic Creutzfeldt-Jakob disease (gCJD) with V180I prion protein gene (PRNP) mutation shows weaker prion protein (PrP) deposition histologically compared with sporadic CJD, and it is more difficult to detect protease-resistant prion protein in immunoblotting. However, we previously reported the autopsy case of a patient with V180I gCJD who was treated with pentosan polysulfate sodium (PPS); th...
Published: July 17, 2023
AI Summary
Heparanase (HPSE) is the only mammalian endo-β-glucuronidase known to catalyze the degradation of heparan sulfate. Dysfunction of HPSE activity has been linked to several disease states, resulting in HPSE becoming the target of numerous therapeutic programs, yet no drug has passed clinical trials to date. Pentosan polysulfate sodium (PPS) is a heterogeneous, FDA-approved drug for the treatment ...
Published: October 22, 2022
AI Summary
Pentosan polysulfate sodium (PPS) is a polysulfated glycosaminoglycan approved for the treatment of interstitial cystitis. It also showed renoprotective effects in chronic kidney injury models, for example, 5/6 nephrectomy and diabetic nephropathy (DN). In the present study, we addressed to evaluate the therapeutic value of PPS in DN of rats in combination with losartan (LSR).
Published: March 16, 2022
AI Summary
Hepcidin which is the crucial regulator of iron homeostasis, produced in the liver in response to anemia, hypoxia, or inflammation. Recent studies have suggested that hepcidin and iron metabolism are involved in osteoporosis by inhibiting osteoblast function and promoting osteoclastogenesis. Pentosan polysulfate (PPS) is a heparin analogue and promising novel therapeutic for osteoarthritis (OA).
Published: March 14, 2022
AI Summary
Renal fibrosis is a common outcome of various renal damage, including diabetic nephropathy (DN), the leading cause of end-stage renal disease. Currently, there are no effective therapies for renal fibrosis. The present study aimed to determine whether pentosan polysulphate sodium (PPS), a FDA approved medication for interstitial cystitis, protects diabetic renal fibrosis..
Published: May 1, 2022
AI Summary
Ulcerative colitis (UC) primarily affects the mucosa of the distal colon. Dysregulated immune response in genetically-prone persons is claimed to be responsible for chronic intestinal inflammation. This study aimed to explore the efficacy and the hematological effects of pentosan polysulfate sodium (PPS) in a dextran sulfate sodium (DSS)-induced colitis model.
Published: September 6, 2021
AI Summary
Chikungunya virus (CHIKV) is an arthropod-borne virus that causes large outbreaks world-wide leaving millions of people with severe and debilitating arthritis. Interestingly, clinical presentation of CHIKV arthritides have many overlapping features with rheumatoid arthritis including cellular and cytokine pathways that lead to disease development and progression. Currently, there are no specifi...
Published: August 8, 2021
AI Summary
Heparin-induced thrombocytopenia (HIT) is characterized clinically by thrombocytopenia, hypercoagulability, and increased thrombosis risk, and serologically by platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies. Heparin-"induced" acknowledges that HIT is usually triggered by a proximate immunizing exposure to heparin. However, certain non-heparin medications (pentosan polysulfa...
Frequently Asked Questions
What is Pentosan Polysulfate?
A compound derived from beechwood. FDA-approved orally (Elmiron) for bladder pain (interstitial cystitis), commonly used as an injection for joint and cartilage repair in osteoarthritis. One of the most popular peptide-adjacent therapies in sports medicine and regenerative clinics. Mimics natural compounds in cartilage to protect joints and reduce inflammation.
What is Pentosan Polysulfate used for?
A compound derived from beechwood. FDA-approved orally (Elmiron) for bladder pain (interstitial cystitis), commonly used as an injection for joint and cartilage repair in osteoarthritis. One of the most popular peptide-adjacent therapies in sports medicine and regenerative clinics. Mimics natural compounds in cartilage to protect joints and reduce inflammation.
What is the dosage for Pentosan Polysulfate?
Oral (Elmiron): 100 mg three times daily for interstitial cystitis. Injectable (compounding): 2-3 mg/kg subcutaneous or intramuscular once or twice weekly for 4-8 weeks for joint applications.
What are the side effects of Pentosan Polysulfate?
Common: bruising, injection site pain, headache, nausea, diarrhea, hair loss (oral). Serious: retinal pigmentary maculopathy with long-term oral use (FDA warning — unique, potentially irreversible vision damage), liver damage (rare). Rare: low platelet count, severe allergic reactions. Regular eye exams recommended with oral use beyond 2 years.
How does Pentosan Polysulfate work?
Pentosan Polysulfate (PPS) is a semi-synthetic, sulfated polysaccharide derived from beechwood hemicellulose (xylan). Its structure consists of a xylose backbone with sulfate ester groups at positions 2 and 3, giving it a high negative charge density similar to heparin and endogenous glycosaminoglycans like heparan sulfate. This polyanionic character is central to its multiple mechanisms of action. In joint and cartilage repair, PPS stimulates chondrocyte proteoglycan synthesis — the production of aggrecan and other proteoglycans that form the hydrated gel matrix of articular cartilage. Proteoglycans are responsible for cartilage's compressive resilience and water retention, and their loss is a hallmark of osteoarthritis. PPS also inhibits matrix metalloproteinases (MMPs), particularly MMP-3, MMP-9, and MMP-13, which are the enzymes responsible for cartilage matrix degradation in osteoarthritis. By simultaneously promoting matrix synthesis and inhibiting matrix breakdown, PPS shifts the balance toward cartilage repair. Additionally, PPS improves synovial fluid viscosity by stimulating hyaluronic acid synthesis from synoviocytes, partially restoring the lubrication and shock-absorbing properties lost in arthritic joints. PPS has several additional pharmacological properties. It inhibits complement activation (particularly the alternative pathway), reducing inflammatory damage to joint tissues. It has fibrinolytic activity — promoting the dissolution of fibrin deposits that can form in inflamed synovial tissue and contribute to joint adhesions. It inhibits certain lipases and has lipid-clearing properties. In its FDA-approved indication (interstitial cystitis), PPS is thought to replenish the damaged glycosaminoglycan layer lining the bladder epithelium, restoring the protective barrier against urine irritants. The recent FDA warning about retinal pigmentary maculopathy with long-term oral use (affecting approximately 1 in 4 long-term users) appears to be related to accumulation of PPS metabolites in the retinal pigment epithelium, where they may disrupt lysosomal function and pigment recycling.
How is Pentosan Polysulfate administered?
Pentosan Polysulfate is administered via oral capsule or subcutaneous/intramuscular injection.
What is the half-life of Pentosan Polysulfate?
The half-life of Pentosan Polysulfate is 20-27 hours.
Is Pentosan Polysulfate legal?
FDA approved as Elmiron (oral) for interstitial cystitis. Injectable form used widely in veterinary medicine and available through compounding pharmacies for human use.
Related Peptides
AEDG Peptide
A tetrapeptide (Ala-Glu-Asp-Gly) identical to Epithalon's core active sequence — effectively the same compound. Studied for telomerase activation and pineal gland regulation, promoting melatonin production and potentially slowing cellular aging through telomere maintenance. Part of the Khavinson bioregulator peptide family developed in St. Petersburg.
Ara-290
A peptide derived from EPO (the hormone that boosts red blood cells) but engineered to keep only the tissue-protective effects — it doesn't increase red blood cells at all. It activates the body's repair receptors to protect tissues and regenerate nerves. Particularly promising for nerve damage and tissue injury from poor blood flow. People use it for diabetic nerve damage and similar conditions.
BPC-157
A healing compound made from a protein found in stomach fluid. It's the most studied peptide for tissue repair, with research showing it helps heal tendons, ligaments, muscles, the gut, and other organs. It's stable enough to survive stomach acid, so you can take it either by injection under the skin or by mouth.
BPC-157 + TB-500
A two-in-one product that pairs BPC-157 and TB-500 to target different healing pathways. BPC-157 focuses on gut, tendon, and ligament repair by supporting blood vessel growth and nitric oxide signaling, while TB-500 helps cells move to injury sites for body-wide tissue repair. The most popular peptide combination for healing and recovery.